Pleiotrophin expression in astrocytic and oligodendroglial tumors and it’s correlation with histological diagnosis, microvascular density, cellular proliferation and overall survival

Bao X, Mikami T, Yamada S, Faissner A, Muramatsu T, Sugahara S (2005) Heparin-binding growth factor, pleiotrophin, mediates neuritogenic activity of embryonic pig brain-derived chondroitin sulfate/dermatan sulfate hybrid chains. J Biol Chem 280:9180–9191 Deuel TF, Zhang N, Yeh HJ, Silos-Santiago I, Wang ZY (2002) Pleiotrophin: a cytokine with diverse functions and a novel signaling pathway. Arch Biochem Biophys 397:162–171 Laaroubi K, Delbe J, Vacherot F, Desgrandes P, Tardieu M, Jaye M, Barritault D, Courty J (1994) Mitogenic and in vitro angiogenic activity of human recombinant heparin affin regulatory peptide. Growth Factors 10:89–98 Merenmies J, Rauvula H (1990) Molecular cloning of the 18-Kda growth-associated protein of developing brain. J Biol Chem 285:16721–16724 Bowden ET, Stoica GE, Wellstein A (2002) Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. J Biol Chem 277:3582–3586 Jager R, List B, Knabbe C, Souttou B, Raulais D, Zeiler T, Wellstein A, Aigner A, Neubauer A, Zugmaier G (2002) Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients. Br J Cancer 86:858–863 Li G, Hu Y, Huo Y, Liu M, Freeman D, Gao J, Liu X, Wu D, Wu H (2006) PTEN deletion leads to up-regulation of a secreted growth factor pleiotrophin. J Biol Chem 281:10663–10668 Kadomatsu K, Muramatsu T (2004) Midkine and pleiotrophin in neural development and cancer. Cancer Lett 204:127–143 Furuta M, Shiraishi T, Okamoto H, Mineta T, Tabuchi K, Shiwa M (2004) Identification of pleiotrophin in conditioned secreted from neural stem cells by SELDI-TOF and SELDI-tandem mass spectrometry. Dev Brain Res 132:189–197 Jung CG, Hida H, Nakahira K, Ikenaka K, Kim HJ, Nishino N (2004) Pleiotrophin mRNA is highly expresses in neural stem (progenitor) cells of mouse ventral mesencephalon and the product promotes production of dopaminergic neurons from embryonic stem cell-derivated nestin-positive cells. FASEB J 18:1237–1239 Lu KV, Jong KA, Kim GY, Singh J, Dia EQ, Yoshimoto K, Wang MY, Cloughesy TF, Nelson SF, Mischel PS (2005) Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J Biol Chem 280:26953–26964 Moon HS, Park WI, Sung SH, Choi EA, Chung HW, Woo BH (2003) Immunohistochemical and quantitative competitive PCR analyses of midkine and pleiotrophin expression in cervical cancer. Gynecol Oncol 88:289–297 Muller S, Kunkel P, Lamszus K, Ulbricht U, Lorente GA, Nelson AM, von Schack D, Chin D, Lohr SC, Westphal M, Melcher T (2003) A role for tyrosine phospatase ζ in glioma cell migration. Oncogene 22:6661–6668 Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A (2002) Pleitrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem 277:14153–14158 Sanson M, Thillet J, Hoang-Xuan K (2004) Molecular changes in gliomas. Curr Opin Oncol 16:607–613 Wu H, Barusevicius A, Babb J, Klein-Szanto AK, Godwin A, Elentsas R, Gelfand JM, Lessin S, Seykora JT (2005) Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential. J Cutan Pathol 32:125–130 Souttou B, Juhl H, Hackenbruck J, Rockseisen M, Klomp HJ, Raulais D, Vigny M, Wellstein A (1998) Relationship between serum concentrations of the growth factor pleiotrophin and pleiotrophin-positive tumors. J Nat Cancer Inst 90:1468–1473 Mentlein M, Held-Feindt J (2002) Pleiotrophin, an angiogenic and mitogenic growth factor, is expressed in human gliomas. J Neurochem 83:747–753 Ulbricht U, Brockmann MA, Aigner A, Eckerich C, Muller S, Fillbrandt R, Westphal M, Lamszus K (2003) Expression and function of the receptor of the protein tyrosine phosphatase ζ and its ligand pleiotrophin in human astrocytomas. J Neuropathol Exp Neurol 62:1265–1275 Malerczyk C, Schulte AM, Czubayko F, Bellon L, Macejak D, Riegel AT, Wellstein A (2005) Ribozyme targeting of the growth factor pleiotrophin in established tumors: a gene therapy approach. Gene Ther 12:339–346 Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215–225 Zhang L, Mabuchi T, Satoh E, Maeda S, Nukui H, Naganuma H (2004) Over expression of heparin-binding growth-associated molecule in malignant glioma cells. Neurol Med Chir 44:637–645 Zhang N, Zhong R, Perez-Pinera P, Herradon G, Ezquerra L, Wang ZY, Deuel TF (2006) Identification of the angiogenesis signaling domain in pleiotrophin defines a mechanism of the angiogenic switch. Biochem Biophys Res Commun 343:653–658 Foehr ED, Lorente G, Kuo J, Ram R, Nikolich K, Urfer R (2006) Targeting of the receptor protein tyrosine phosphatase β with a monclonal antibody delays tumor growth in a glioblastoma model. Cancer Res 66:2271–2278 Ulbricht U, Eckerich C, Fillbrandt R, Westphal M, Lamszus K (2006) RNA interference targeting protein tyrosine phosphatase ζ/receptor-type protein tyrosine phosphatase β supresses glioblastoma growth in vitro and in vivo. J Neurochem 98:1497–1506 Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828